BioSpace News Archive

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in two Phase 1/2a clinical trials of ARO-MUC5AC and ARO-RAGE, the company’s investigational RNA interference (RNAi) therapeutics designed to reduce production the of mucin 5AC (MUC5AC).

Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros’ Ongoing Clinical Programs.

Ayala Pharmaceuticals, Inc. today announced positive interim results from Part A of the ongoing RINGSIDE Pivotal Phase 2/3 clinical trial evaluating AL102 in desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibitor (GSI).

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced today the full cash pre-payment of its unsecured convertible promissory note dated November 4, 2020, as amended November 16, 2021 (the “Note”).

Gritstone bio, Inc. announced that the company’s Board of Directors has granted eight employees nonqualified stock options to purchase an aggregate of 67,550 shares of its common stock with an exercise price of $2.66, which is equal to the closing price of Gritstone’s common stock on June 23, 2022, the grant date of the awards.

Oryzon Genomics, S.A. announced today the entry into a convertible bonds financing agreement (the “Issuance Agreement”) with Nice & Green in bonds convertible into new shares for a total amount of €20 Million.

Helio Genomics, and its commercial partner, Fulgent Genetics announced that the American Medical Association has issued a new Category I Current Procedural Terminology Proprietary Laboratory Analyses code for HelioLiver™, enabling a reimbursement pathway for potential increased access and broader adoption of innovative surveillance tests for liver cancer in the U.S. The code will become effective on October 1, 2022.

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”) application for a Phase 1 study of its six-month or longer subdermal formulation of nalmefene.

Precigen enters into agreement to sell wholly-owned subsidiary Trans Ova Genetics to URUS for $170 million in upfront cash and up to $10 million earn-out over two years; close expected in Q3 2022.

Bringing More Than 20 Years of Experience to Sonendo, Lindberg Will Focus on Accelerating Sales Growth.